EDIT101

CAMBRIDGE, Mass., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that an abstract featuring initial clinical data from the BRILLIANCE clinical trial of EDIT-101…

No serious adverse events or dose-limiting toxicities observed to date Efficacy signals in the mid-dose cohort provide initial support for clinical benefits Treatment in the adult high-dose cohort continues and pediatric mid-dose cohort…

Data to include patient safety assessments and a preliminary analysis of secondary endpoints to evaluate biological activity Abstract selected for oral presentation on September 29 Company to host webcast investor event following the…

IDMC endorsed proceeding with first pediatric cohort based on a review of clinical safety data from adult low-dose and adult mid-dose cohorts Concurrently enrolling the adult high-dose cohort in the BRILLIANCE trial Company plans to…